IL1B and familial pancreatic carcinoma: A study revealed that an inflammatory interplay between IL-1β-expressing TAMs and pancreatic cancer cells drives disease progression and that targeting IL-1β activity could reprogram the immune microenvironment and control tumor growth [33].